Page last updated: 2024-09-03

tamsulosin and Bladder Diseases

tamsulosin has been researched along with Bladder Diseases in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	3 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chung, JI; Hong, JH; Jung, TY; Kang, TW; Kwak, C; Kwon, SY; Lee, JY; Lee, KS; Seo, SI; Yoo, TK; Yun, SJ	1
Imazumi, K; Masuda, N; Noguchi, Y; Ohtake, A; Sakamoto, K; Takeda, M; Ueshima, K	1
Kida, J; Matsuya, H; Okada, H; Sekido, N; Wakamatsu, D	1

Trials

1 trial(s) available for tamsulosin and Bladder Diseases

Article	Year
Comparison of the Effect of Naftopidil 75 mg and Tamsulosin 0.2 mg on the Bladder Storage Symptom With Benign Prostatic Hyperplasia: Prospective, Multi-institutional Study. Urology, 2018, Volume: 111 Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Humans; Male; Naphthalenes; Piperazines; Prospective Studies; Prostatic Hyperplasia; Tamsulosin; Treatment Outcome; Urinary Bladder; Urinary Bladder Diseases	2018

Article

Year

Comparison of the Effect of Naftopidil 75 mg and Tamsulosin 0.2 mg on the Bladder Storage Symptom With Benign Prostatic Hyperplasia: Prospective, Multi-institutional Study.

Urology, 2018, Volume: 111

Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Humans; Male; Naphthalenes; Piperazines; Prospective Studies; Prostatic Hyperplasia; Tamsulosin; Treatment Outcome; Urinary Bladder; Urinary Bladder Diseases

2018

Other Studies

2 other study(ies) available for tamsulosin and Bladder Diseases

Article	Year
ASP6432, a type 1 lysophosphatidic acid receptor antagonist, reduces urethral function during urine voiding and improves voiding dysfunction. European journal of pharmacology, 2019, Mar-15, Volume: 847 Topics: Animals; Female; Male; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Adrenergic, alpha-1; Receptors, Lysophosphatidic Acid; Tamsulosin; Urethra; Urinary Bladder; Urinary Bladder Diseases; Urine	2019
Effects of α1 antagonist and cholinesterase inhibitor on cystometric parameters in lumbar canal stenosis rats with underactive bladder. Urology, 2014, Volume: 84, Issue:5 Topics: Administration, Oral; Adrenergic alpha-1 Receptor Antagonists; Animals; Cholinesterase Inhibitors; Constriction, Pathologic; Female; Pyridinium Compounds; Rats; Rats, Wistar; Silicon; Sulfonamides; Tamsulosin; Urinary Bladder; Urinary Bladder Diseases; Urinary Bladder, Neurogenic; Urinary Retention; Urination; Urodynamics	2014

Article

Year

ASP6432, a type 1 lysophosphatidic acid receptor antagonist, reduces urethral function during urine voiding and improves voiding dysfunction.

European journal of pharmacology, 2019, Mar-15, Volume: 847

Topics: Animals; Female; Male; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Adrenergic, alpha-1; Receptors, Lysophosphatidic Acid; Tamsulosin; Urethra; Urinary Bladder; Urinary Bladder Diseases; Urine

2019

Effects of α1 antagonist and cholinesterase inhibitor on cystometric parameters in lumbar canal stenosis rats with underactive bladder.

Urology, 2014, Volume: 84, Issue:5

Topics: Administration, Oral; Adrenergic alpha-1 Receptor Antagonists; Animals; Cholinesterase Inhibitors; Constriction, Pathologic; Female; Pyridinium Compounds; Rats; Rats, Wistar; Silicon; Sulfonamides; Tamsulosin; Urinary Bladder; Urinary Bladder Diseases; Urinary Bladder, Neurogenic; Urinary Retention; Urination; Urodynamics

2014